-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Edit | Wang Cong's glioma is the most common malignant tumor of the central nervous system.
Although in-depth research has been conducted in the past few decades, the treatment methods and effects are extremely limited.
For patients with glioblastoma, the median survival time is only 15 months.
At present, surgical resection and postoperative concurrent radiotherapy and chemotherapy are the main treatment methods, but their effects are limited.
Some immunotherapies that are undergoing clinical trials have a certain effect on primary or recurrent gliomas, but there are still many problems that need to be resolved.
A research team led by Dr.
Chen Gong, a former professor at Pennsylvania State University and now director of the Brain Repair Center of Jinan University in China, has developed a new type of gene therapy that can reprogram glioma cells into functional neurons, which can provide for the treatment of gliomas.
New ideas.
The research results were published in Cancer Biology Medicine on March 22, 2021 under the title: Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion.
Glioma is a tumor derived from malignant glial cells, and its biological characteristics are characterized by malignant proliferation and invasion.
Chen Gong’s team previously published a series of research results, which proved that after overexpression of neuronal transcription factors such as NeuroD1 and Dlx2, astrocytes in the brain can be directly transformed into functional neurons in situ.
In this work, Chen Gong's team further expanded the study of astrocytes to astroglioma cells, and found that nerve transcription factors can also effectively convert astroglioma cells into neurons.
Neurons transformed from glioma cells are marked in red by glioma cells, and neurons marked in green.
Professor Chen Gong said when explaining their original intention to develop this new technology: “We have developed for glioma.
Cell transformation therapy is very unique.
It is completely different from the conventional anti-cancer methods that are usually aimed at killing cancer cells.
The side effects are also small.
The method of killing cancer cells often inevitably brings harm to normal cells.
On the contrary, when we use When cell transformation gene therapy transforms glioma cells into neurons, the effect on normal cells is very limited.
"
Dr.
Wang Xin, the first author of the paper, said: “Another important advantage of our gene therapy is that after overexpressing NeuroD1 or other neural transcription factors in glioma cells, the glioma cells stop proliferating immediately before turning into nerves.
element.
Thus, this transcription factor-based gene therapy can prevent the rapid proliferation of malignant glioma cells, making it possible to greatly extend the treatment time window.
"
Although Professor Chen Gong and his colleagues are very excited about their cell transformation therapy, they also admit that this new therapy is still in the early stages of development, and there are many technical issues that need to be resolved, such as the need to develop a safe and effective virus delivery system, and It can target glioma cells instead of normal cells, and detect whether neural transcription factors have potential side effects.
They also plan to combine cell transformation therapy with other interventions in order to achieve a better synergistic treatment of glioma.
In addition to Professor Chen Gong and Dr.
Wang Xin, other contributors to this work include Dr.
Pei Zifei, Aasma Hossain, and Bai Yuting from Pennsylvania State University.
This work was supported by Professor Chen Gong from Charles H.
"Skip" Smith Endowment Fund.
Link to the paper: https://doi.
org/10.
20892/j.
issn.
2095-3941.
2020.
0499 is open for reprint
Although in-depth research has been conducted in the past few decades, the treatment methods and effects are extremely limited.
For patients with glioblastoma, the median survival time is only 15 months.
At present, surgical resection and postoperative concurrent radiotherapy and chemotherapy are the main treatment methods, but their effects are limited.
Some immunotherapies that are undergoing clinical trials have a certain effect on primary or recurrent gliomas, but there are still many problems that need to be resolved.
A research team led by Dr.
Chen Gong, a former professor at Pennsylvania State University and now director of the Brain Repair Center of Jinan University in China, has developed a new type of gene therapy that can reprogram glioma cells into functional neurons, which can provide for the treatment of gliomas.
New ideas.
The research results were published in Cancer Biology Medicine on March 22, 2021 under the title: Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion.
Glioma is a tumor derived from malignant glial cells, and its biological characteristics are characterized by malignant proliferation and invasion.
Chen Gong’s team previously published a series of research results, which proved that after overexpression of neuronal transcription factors such as NeuroD1 and Dlx2, astrocytes in the brain can be directly transformed into functional neurons in situ.
In this work, Chen Gong's team further expanded the study of astrocytes to astroglioma cells, and found that nerve transcription factors can also effectively convert astroglioma cells into neurons.
Neurons transformed from glioma cells are marked in red by glioma cells, and neurons marked in green.
Professor Chen Gong said when explaining their original intention to develop this new technology: “We have developed for glioma.
Cell transformation therapy is very unique.
It is completely different from the conventional anti-cancer methods that are usually aimed at killing cancer cells.
The side effects are also small.
The method of killing cancer cells often inevitably brings harm to normal cells.
On the contrary, when we use When cell transformation gene therapy transforms glioma cells into neurons, the effect on normal cells is very limited.
"
Dr.
Wang Xin, the first author of the paper, said: “Another important advantage of our gene therapy is that after overexpressing NeuroD1 or other neural transcription factors in glioma cells, the glioma cells stop proliferating immediately before turning into nerves.
element.
Thus, this transcription factor-based gene therapy can prevent the rapid proliferation of malignant glioma cells, making it possible to greatly extend the treatment time window.
"
Although Professor Chen Gong and his colleagues are very excited about their cell transformation therapy, they also admit that this new therapy is still in the early stages of development, and there are many technical issues that need to be resolved, such as the need to develop a safe and effective virus delivery system, and It can target glioma cells instead of normal cells, and detect whether neural transcription factors have potential side effects.
They also plan to combine cell transformation therapy with other interventions in order to achieve a better synergistic treatment of glioma.
In addition to Professor Chen Gong and Dr.
Wang Xin, other contributors to this work include Dr.
Pei Zifei, Aasma Hossain, and Bai Yuting from Pennsylvania State University.
This work was supported by Professor Chen Gong from Charles H.
"Skip" Smith Endowment Fund.
Link to the paper: https://doi.
org/10.
20892/j.
issn.
2095-3941.
2020.
0499 is open for reprint
